Cited by 108Down syndrome and intellectual disability researchAlzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Increased plasma amyloid β protein 1–42 levels in Down syndrome

Mehta, Pankaj D, Dalton, Arthur J, Mehta, Sangita P, Kim, Kwang Soo, Sersen, Eugene A, Wisniewski, Henryk M·1998·Neuroscience Letters

Abstract

Amyloid beta protein 1-40 (A beta40) and A beta42 levels were quantitated in plasma from 43 persons with Down syndrome (DS; 26-68 years of age), 43 age-matched normal controls, and 19 non-DS mentally retarded (MR) persons (26-91 years of age) by using a sandwich enzyme linked immunosorbent assay. A beta40 levels were higher in DS and MR than controls, but were similar between DS and MR groups. A beta42 levels were higher in DS than controls or MR persons. The ratios of A beta42/A beta40 were higher in DS than controls or MR persons. The findings are consistent with those seen in DS brains.

Integrity signals

Registry

Crossref · 10.1016/s0304-3940(97)00966-x

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. Mehta, 1997, Plasma amyloid β (Aβ) 1–42 levels are increased in Down syndrome (DS) but not in Alzheimer disease (AD), Ann. Neurol. (Abstr.), 42, 400
  2. Wisniewski, 1994, Age-associated development of diffuse and thioflavin-S-positive plaques in Down syndrome, Dev. Brain Dysfunct., 7, 330

Cited by

Sorted by citations

Authors
Mehta, P. D., Dalton, A. J., Mehta, S. P., Kim, K. S., Sersen, E. A., & Wisniewski, H. M.
Corresponding author
Mehta, Pankaj D
Venue
Neuroscience Letters
Publisher
Elsevier BV
Published
1998-01
Volume
241
Issue
1
Pages
13-16
ISSN
0304-3940 (ISSN-L)
OpenAlex
W2057996446
Cited by
108
References
18
Citations by year
2024: 1 · 2021: 3 · 2019: 5 · 2018: 1 · 2017: 1 · 2016: 2 · 2015: 4 · 2014: 2 · 2013: 1 · 2012: 2
FWCI
16.14
Type
journal article
Language
en
Open access
closed
Locations
  • Neuroscience Letters (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (5r01ag011290-05)
  • National Institute on Aging (AG11290)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Down syndrome and intellectual disability research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
Down syndrome, amyloid-beta, amyloid-beta 42, Aβ40, plasma biomarkers, intellectual disability, Alzheimer's disease
MeSH terms
Adult, Aged, Aged, 80 and over, Down Syndrome, Female, Humans, Male, Intellectual Disability, Middle Aged, Peptide Fragments, Trisomy, Amyloid beta-Peptides, Gene Dosage

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review